Home 'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership
 

Keywords :   


'Suicidal ideation' leads to end of Amgen-AstraZeneca drug partnership

2015-05-26 23:58:21| Biotech - Topix.net

Amgen has pulled out of a co-development deal it had with AstraZeneca for an experimental psoriasis drug, which was in the late stages of clinical development, after observing "suicidal ideation" in some patients during clinical testing of the new drug candidate. Dr. Sean E. Harper , executive vice president of research and development at Amgen, said the company believed the likelihood of the drug being required to carry warning labels of suicide risk would limit the potential market for the treatment.

Tags: end drug leads partnership

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »